WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 1-December 2016 (data as of 18-November-2016)
Next overall update June 2017
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 77'0001 Infant (under 12 months) mortality rate: 02
GDP / capita (US$): 101'9261 Child (under 5 years) mortality rate: 02

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 567  557  545  532  520  436  382  364 
Births
Surviving infants
Pop. less than 5 years 32  31  30  30  29  28  23  21 
Pop. less than 15 years 93  93  92  91  90  83  66  68 
Female 15-49 years 140  138  136  133  130  109  97  91 

Number of reported cases

(Click for retrospective incidence data for Luxembourg)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  16  63 
Mumps
ChartChart
 
Pertussis
ChartChart
  30  10  46 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Luxembourg)
Vaccine year result method % card seen                                                
BCG         
DTP1          99*  99*  99*  99*  99* 
DTP3          99  99  99  99*  99  90 
DTP4          95 
IPV1          99* 
HepB_BD         
HepB3          99  94  94  94  95 
Hib3          99  99  99  99  99 
JapEnc         
MCV1          99  99  99  99  96  80 
MCV2          86  86  86  86 
PCV1          97  97  95 
PCV3          95  95  95  95  86 
Pol3          99*  99*  99*  99*  96  90 
Rota1          91  91 
RotaC          89  89  89  89 
RCV1          99  99  99  99  96 
TT2plus         
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2017

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Luxembourg)
DTP1
ChartChart
  99  99  99  99  99  99  96 
DTP3
ChartChart
  99  99  99  99  99  99  90 
HepB3
ChartChart
  99  94  94  94  95  77 
HepB_BD
ChartChart
 
Hib3
ChartChart
  99  99  99  99  99  93 
MCV1
ChartChart
  99  99  99  99  96  93  80 
MCV2
ChartChart
  86  86  86 
PCV3
ChartChart
  95  95  95  95  86 
Pol3
ChartChart
  99  99  99  99  96  99  90 
RCV1
ChartChart
  99  99  99  99  96  93 
RotaC
ChartChart
  89  89  89  89  88 

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaPHibHepIPV 2, 3, 13 months; Yes
DTaPHibIPV 4 months; Yes
DTaPIPV 5-6 years; 15-16 years; Yes
HPV 11 years;+6 months; Yes
HepA Yes recommended for travellers and specific risk groups
HepB_Adult Yes recommended for risk groups
HepB_Pediatric Yes recommended at birth for children of Hep B positive mothers
Influenza_Adult > 65 years; Yes chronic illness, pregnant women, health care workers and other risk groups
Influenza_Pediatric Yes children with chronic illness
MMRV 12, 15-23 months; Yes
MenC_conj 13 months; Yes
Pneumo_conj 2, 4, 12 months; Yes
Pneumo_ps >= 60 years; Yes
Rotavirus 2, 3 months; Yes
Typhoid travelers
YF travelers

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR     NA  NA  NA  NA  NA 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number     NA  NA  NA  NA  NA 

System performance

Total Nº districts in country number     NA    NA  NA 
Nº districts with DTP3 coverage >=80% number            
% of districts with DTP3 coverage >=80% From 0 to 100%              
Nº districts with measles (MCV1) coverage >=95% number              
% of districts with MCV1 coverage >=95% From 0 to 100%              

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND     Yes  Yes  Yes  Yes   
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR     Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR     Yes  Yes  Yes  Yes   

Sources

 1  "The 2016 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.